AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.
Sanofi and Regeneron Pharmaceuticals' Dupixent was approved in Canada for expanded use as an add-on maintenance treatment in certain patients with severe asthma.
Nasacort Allergy 24HR Nasal Spray is now available over-the-counter in the United States. The medication is designed to relieve the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older.